Arellano, M. L., Thirman, M. J., DiPersio, J. F., Heiblig, M., Stein, E. M., Schuh, A. C., Zucenka, A., Botton, S. D., Grove, C. S., Mannis, G. N., Papayannidis, C., Perl, A. E., Issa, G. C., Aldoss, I., Bajel, A., Dickens, D. S., Kühn, M. W. M., Mantzaris, I., Raffoux, E., Traer, E., Amitai, I., Döhner, H., Greco, C., Kovacsovics, T., McMahon, C. M., Montesinos, P., Pigneux, A., Shami, P. J., Stone, R. M., Wolach, O., Harpel, J. G., Chudnovsky, Y., Yu, L., Bagley, R. G., Smith, A. R., Blachly, J. S. (2025). Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. https://doi.org/10.1182/blood.2025028357